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The Relationship between Carnitine Levels and Lipid
Peroxidation in Glial Brain Tumors
Aim: It is assumed that reactive oxygen species and lipid peroxidation cause cell membrane damage and play
a role in oncogenesis. Carnitine and acyl esters, which play a role in intracellular short-, medium-, and longchain fatty acid metabolism, are one of the defense mechanisms against free radical toxicity. It is thought that
the protective effects of carnitine are related with its role in lipid metabolism. In our study, we analyzed the
relation between malondialdehyde (MDA) and free carnitine, and C2, C3, C4, C5, C6, C8, C10, C12, C14:1,
C14, C16:1, C16, C18:1, C18, C20:4 carnitine levels in glial tumors [glioblastoma multiforme (GBM) (n =
29), high-grade astrocytoma (n = 8) and low-grade astrocytoma (n = 8)] to determine whether there is a
relation between carnitine-acyl carnitines and lipid peroxidation in carcinogenesis.
Materials and Methods: The present study examined the free carnitine and C2, C3, C4, C5, C6, C8, C10,
C12, C14:1, C14, C16:1, C16, C18:1, C18, C20:4 levels of glial tumors in tandem mass spectrometry. We
measured MDA levels using HPLC system.
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Results: There was a significant correlation between MDA and C20:4 carnitine levels in GBM. C20:4 carnitine
levels increased with increasing MDA levels (p = 0.000, r = 0.916), but no significant correlation was found
in the other groups.
Conclusions: In conclusion, measurement of only carnitine-MDA relation did not reflect any significant
correlation. Detailed studies, including measurement of parameters showing antioxidant status and tumor
cellular metabolism, are necessary.
Key Words: Carnitine, lipid peroxidation, tandem mass spectrometry, HPLC

Glial Beyin Tümörlerinde Karnitin Düzeyleri ve Lipid Peroksidasyonu
Arasındaki İlişki
Amaç: Serbest oksijen radikallerinin ve lipid peroksidasyonunun hücre zarı hasarına neden olduğu ve
onkogenezde rol oynadığı düşünülmektedir. Hücre içi kısa, orta ve uzun zincirli yağ asidi metabolizmasında
rol oynayan karnitin ve açil esterleri, serbest radikal toksisitesine karşı savunma mekanizmalarından birisidir.
Karnitinin koruyucu etkilerinin lipid metabolizması üzerindeki rolüyle ilişkili olduğu düşünülmektedir.
Çalışmamızda, karsinogenezisde karnitin-açilkarnitinlerin lipid peroksidasyonuyla arasında bir ilişki olup
olmadığını açıklamak için glial tümörlerdeki (glioblastoma multiforme (GBM) n = 29, yüksek grade
astrositoma n = 8 and düşük grade astrositoma n = 8) MDA ve serbest karnitin, C2, C3, C4, C5, C6, C8, C10,
C12, C14:1, C14, C16:1, C16, C18:1, C18, C20:4 karnitin düzeyleri arasındaki ilişkiyi inceledik.
Yöntem ve Gereç: Glial tümörlerdeki serbest karnitin ve C2, C3, C4, C5, C6, C8, C10, C12, C14:1, C14,
C16:1, C16, C18:1, C18, C20:4 karnitin düzeyleri ardışık kütle spektrometrisinde çalışıldı. MDA düzeyleri ise
HPLC sistemi kullanılarak ölçüldü.
Bulgular: GBM’ de MDA ve C20:4 karnitin düzeyleri arasında anlamlı bir korelasyon bulundu. MDA düzeyleri
artarken C20:4 karnitin düzeylerinin de arttığı görüldü (p = 0.000, r = 0.916). Fakat diğer gruplar arasında
anlamlı bir korelasyon görülmedi.
Sonuç: Sonuç olarak sadece MDA-karnitin ilişkisinin ölçümü anlamlı bir korelasyon yansıtmamaktadır.
Antioksidan yapılar ve tümör hücre metabolizmasını gösteren parametreleri de içeren daha kapsamlı
çalışmalarla konunun incelenmesi gerekmektedir.
Anahtar Sözcükler: Karnitin, lipid peroksidasyonu, ardışık kütle spektrometrisi, HPLC

drnbayraktar@yahoo.com
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Introduction
Reactive oxygen species (ROS) are known to be
implicated in signaling pathways regulating cell growth
(1) and cell status redox control. However, when
produced in excess, ROS exert detrimental effects that
are able to damage cell macromolecules, such as DNA,
lipids or proteins (2). Among these targets, lipid
peroxidation is particularly more damaging because it
facilitates propagation of free radical reactions. It is
assumed that ROS and lipid peroxidation cause cell
membrane damage and play a role in oncogenesis. ROS
may act in several steps in carcinogenesis. It has been
shown that the oxidative mechanism may have a potential
role in the initiation, progression and malignant
transformation of carcinogenesis (3,4). ROS are involved
in the pathogenesis of three common tumors: lung
cancer, hepatocellular carcinoma, and carcinoma of
prostate (5).
Lipid peroxidation is a harmful chain reaction. It
directly affects cell membrane structure. In addition, it
produces reactive aldehydes, and thusly damages other
cell components. Peroxidation of three or more pair
bonds causes destruction of lipid hydroperoxides and
produces malondialdehyde (MDA). MDA causes
transversal binding and polymerization of membrane
components. MDA is a good parameter of the degree of
lipid peroxidation (6).
The brain is dependent on aerobic energy production,
which requires constant flow of oxygen. The high level of
polyunsaturated fatty acids in cell membranes (7) makes
the brain particularly vulnerable to free oxygen radical
damage. Iron-rich areas in the brain also play an essential
role in generating ROS (8). The sensitivity of brain tissue
to oxidative stress and the effect of free radicals in
oncogenesis led us to consider the relation between brain
tumors and oxidative stress.
Carnitine has two main functions: transporting longchain fatty acids into the mitochondrial matrix for ß
oxidation to provide cellular energy and modulating the
rise in intramitochondrial acyl-CoA/CoA ratio, which
relieves the inhibition of many intramitochondrial
enzymes involving glucose and amino acid catabolism (9).
The carnitine shuttle in brain mitochondria revealed a
different substrate specificity than in other tissues; the
294
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system was found more specific towards short- than
long-chain acyl derivatives of carnitine (10). It is
postulated that its major role in the adult brain would be
translocation of acetyl moieties from mitochondria into
the cytoplasm for acetylcholine synthesis. Acetylcholine
synthesis is stimulated by carnitine and choline in a
synergistic way in cells utilizing glucose as the main
energetic substrate (11). Thus, it seems reasonable to
claim for acetyl-L-carnitine (C2 carnitine) a pivotal role in
the regulation of carbohydrate and lipid metabolism in
the central nervous system (9). In some experiments, it is
suggested that C2 carnitine has neurotrophic and
neuroprotective activities (12).
Carnitine and carnitine esters protect cells, which play
a role in attenuating oxidative damage (13). Carnitine
contributes to the depression of oxygen radical formation
by their regulatory effects on cell energy metabolism and
stabilization effects on cell membrane phospholipids.
Thus, it is concluded that both endogenous scavenging
systems and regulation of energy metabolism play an
important role in neuroprotective effects against oxygen
free radicals (14). Carnitine is also associated with
buffering of excess acyl-Co A, which is potentially toxic to
the cells, and it was reported that L-carnitine has a
protective effect on lipid peroxidation by reducing the
formation of hydrogen peroxide.(15) L-carnitine also
improved antioxidant status in rats and showed free
radical scavenging activity as well (16).
There is sufficient detailed information about the
effect of carnitine in cancer patients. The small number of
studies about carnitine and its acyl esters in brain tumor
cells expose the need for a new clinical approach on this
subject. In our study, we analyzed the levels of MDA and
free carnitine, and C2, C3, C4, C5, C6, C8, C10, C12,
C14:1, C14, C16:1, C16, C18:1, C18, C20:4 carnitine in
glial tumors to demonstrate if there is any relation
between carnitine-acyl carnitines and lipid peroxidation in
carcinogenesis.

Materials and Methods
With the approval of the local ethics committee,
specimens used in this study were obtained from patients
with glial tumors who were seen at Gazi University,
Department of Neurosurgery (Table 1). Forty-five
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Table 1. Working groups included in the study according to pathological diagnosis (brain tumor
tissues of patients at Gazi University, Department of Neurosurgery).
Tissue Groups

n

Female

Male

Glioblastoma multiforme

29

11

18

32-87

High-grade astrocytoma

8

3

5

18-75

Low-grade astrocytoma

8

3

5

34-51

Total

45

17

28

–

patients were enrolled in the study following provision of
informed consent. All tumor groups underwent surgical
resection after a full clinical and radiological evaluation.
The tumor was resected microsurgically as a gross total.
The diagnosis was confirmed by histopathologic
evaluation. They were obtained during surgery and
stored at –80°C.
Tissue MDA levels were detected as MDA-TBA
(thiobarbituric acid) complexes in high performance liquid
chromatography (HPLC) using Agarwal et al.’s (17)
method. 50 mg tumor tissues were homogenized with
0.95 ml 1.95% KCl. Samples were centrifuged at 14000
rpm for 10 min at 4°C and then supernatants were
separated. Standards were prepared from 1,1,3,3tetraethoxypropone (TEP) at 20 μM, 10 μM, 5 μM, and
2.5 μM concentrations.
50 μl supernatant or 50 μl standard, 50 μl 0.05%
BHT, 400 μl 0.44 M H3PO4, and 100 μl TBA were added
into tubes, vortexed and closed tightly. They were
incubated at 100°C for 1 h. They were treated with 250
μl n-butanol after cooling. Tubes were vortexed for 5 min
and centrifuged at 14000 rpm for 3 min. A 20 μl sample
from the n-butanol layer was injected into HPLC (Waters).
Fluorescence detector was used for HPLC. A 20 μl sample
was injected into the device at 1 min intervals.
Methanol/phosphate buffer (40/60, v/v) was used for
mobile phase with 1 ml/min flow rate. The fluorescence
detector was set at an excitation wavelength of 515 nm
and emission wavelength of 553 nm. The column was 5 μl
ODS 100x4.6 mm placed in a column warmer set to 37°C.
Free carnitine and acylcarnitine derivatives were
measured according to Chace et al.’s (18) tandem mass
spectrophotometric (TMS) method. Free carnitine and
acylcarnitine derivative levels in tissue (19) were detected
at Micromass Quatro II TMS using ESI ionization source.
Samples were given to the system with a Jasca PU-980

Age Interval

pump and a Jasca AS-950 auto sampler. Nitrogen and
argon gases were used for analyses. Free and
acylcarnitine reference standard (Cambridge Isotope
Laboratories, USA) was used as the standard.
50 mg tissue was homogenized with 2 ml methanol.
Materials were placed on shaker for 30 min and left at 80°C for another 30 min for deproteinization. They were
centrifuged at 14000 rpm for 5 min. 100 μl supernatant
was transferred into microtiter plate, where 100 μl of
1/245 diluted internal standard was added. Samples were
evaporated under nitrogen for derivatization. 60 μl
butanyl HCl (acetyl chloride/n-butanol, 1/10) was added
and the plate was covered and incubated at 65°C for 20
min. After evaporation under nitrogen, 100 μl
acetonitril/H2O (80/20) was added to samples.10 μl of
solution was injected into TMS for analysis.
Statistical Analysis
SPSS software for Windows (version 11.0) was used
for evaluating data about acylcarnitine levels of brain
tumors, statistical calculations of the groups and standard
deviations (±SD), and for determining the significance of
the differences between the groups’ mean values.
Mann–Whitney U test was applied to compare differences
between the groups. Spearmen correlation test was used
to show if there was a significant relation between MDA
and carnitine levels. A p value of less than 0.05 (P <
0.05) was considered statistically significant.
Results
MDA levels of glioblastoma multiforme (GBM) and
high- and low-grade astrocytoma tumor groups were
calculated as nmol/g damp tissue (Table 2).
There was no statistically significant difference
between MDA levels in the tumor groups (P > 0.05).
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Table 2. MDA levels of tumor groups (mean ± SD).
GROUPS

n

MDA Levels
(nmol / g damp tissue)

Glioblastoma multiforme

29

29.9 ± 8.1

High-grade astrocytoma

8

27.6 ± 4.5

Low-grade astrocytoma

8

26.5 ± 4.3

Free carnitine, acetylcarnitine (C2), propionylcarnitine
(C3), butyrylcarnitine (C4), isovalerylcarnitine (C5),
hexanoylcarnitine (C6), octanoylcarnitine (C8),
decanoylcarnitine (C10), dodecanoylcarnitine (C12),
tetradecanoylcarnitine (C14:1), myristoylcarnitine (C14),
palmitoleoylcarnitine (C16:1), palmitoylcarnitine (C16),

Turk J Med Sci

oleoylcarnitine (C18:1), stearoylcarnitine (C18), and
arachidonoylcarnitine (C20:4) levels of GBM, and highand low-grade astrocytoma tumor groups are given and
compared in Table 3.
C2, C18 and C18:1 carnitine levels were significantly
decreased in low-grade astrocytomas when compared with
high-grade astrocytomas. C16:1 carnitine was increased;
however, there were no apparent differences in other
carnitine levels. Most of the carnitine levels showed
decrease in astrocytomas compared with the GBM group
(except C16:1 level in high-grade astrocytomas).
MDA and C20:4 carnitine levels were increased in
GBM according to Spearman correlation analysis (Figure).
No significant correlation was found between the other
parameters.

Table 3. Carnitine levels of glioblastoma multiforme, high-grade astrocytoma, and low- grade
astrocytoma tumor groups (mean ± SD).
Acylcarnitine
derivatives

Glioblastoma
Multiforme
(nmol/g damp tissue)

High-Grade
Astrocytoma
(nmol/g damp tissue)
b

Low-Grade
Astrocytoma
(nmol/g damp tissue)

152.0 ± 82.0

67.1± 31.0

C2

65.7 ± 26.8

56.7 ± 16.9

C3

6.5 ± 2.9

1.1 ± 0.5

b

1.1 ± 0.4

b

C4

8.1 ± 3.7

4.1 ± 1.8

b

2.8 ± 0.9

b

C5

3.3 ± 1.2

1.3 ± 0.8

b

1.0 ± 0.3

b

C6

1.5 ± 0.6

0.8 ± 0.2

b

0.8 ± 0.4

b

C8

0.13 ± 0.05

0.08 ± 0.03

b

0.08 ± 0.04

a

C10

0.19 ± 0.08

0.11 ± 0.05

a

0.10 ± 0.03

b

C12

0.95 ± 0.50

0.39 ± 0.18

b

0.36 ± 0.09

b

C14:1

0.51 ± 0.20

0.43 ± 0.24

d

0.35 ± 0.10

a

1.5 ± 0.6

1.4 ± 0.8

0.9 ± 0.3

C16:1

1.15 ± 0.58

1.60 ± 0.86

0.73 ± 0.28

C16

11.6 ± 5.5

8.5 ± 4.0

5.9 ± 1.4

C18:1

5.4 ± 1.7

4.8 ± 1.3

2.9 ± 0.5

b.d

C18

9.7 ± 3.1

4.3 ± 1.3

1.6 ± 0.4

b.d

0.34 ± 0.09

0.10 ± 0.05

C14

C20:4

52.0 ± 19.0

b

Free Carnitine

37.5 ± 9.4

b

b

b.c

b

c

b

0.10 ± 0.04

b

* Glioblastoma multiforme tumor group compared with high-grade astrocytoma, low-grade astrocytoma
tumor a P < 0.05 - b P < 0.01.
* High-grade astrocytoma group compared with low-grade astrocytoma tumor group c P < 0.05 d
P < 0.01.
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Figure. The correlation between MDA levels and C20:4 carnitine in
GBM.

Discussion
In recent years, carnitine and its acyl esters have been
considered as part of the defense biochemical network
devoted to protection against free radical toxicity in
various treatment areas of medicine. Findings in several
recent studies have suggested that carnitine and some of
its acyl esters may have a beneficial effect in those
pathologic conditions where the free radicals are blamed
as potential mediators of cellular damage (20). Lcarnitine can increase the metabolic efficiency of
mitochondria and cause a redistribution of the metabolic
workload, resulting in increased cellular efficiency and
possibly a decrease in the rate at which mitochondrially
derived oxidants are produced (21). In addition, in vitro
evidence would support the concept that acetyl-Lcarnitine might posses a direct antioxidant activity (22). It
is demonstrated that acetyl-L-carnitine plays an important
role in carbohydrate and lipid metabolism in the central
neural system (12). In many studies, it was shown that
acetyl-L-carnitine has neurotrophic and neuroprotective
activities (23). It is known that carnitine and its species
improve myocardial function and metabolic parameters
developed in myocardial ischemia and ischemiareperfusion damage (14). Reznick et al. (23) showed Lpropionyl carnitine protects the heart via two
mechanisms: 1) it combines the iron that is necessary for
the production of hydroxyl radicals, and 2) it serves as a
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source of energy. All these are supported by carnitine,
which decreases heart lipid peroxidation stimulated by
doxorubicin (13), and propionyl carnitine, which
decreases lipoperoxide production that occurs during
ischemia reperfusion damage in the rat heart (24).
Furthermore, the protective effects of carnitine in the
brain were shown, but the characteristics of these
protective effects can not be clarified. Koudelova et al.
(25) found that carnitine protects the rat brain from lipid
peroxidation and also partially improves neuron
excitability after low pressure hypoxia. Carnitine
contributes to the depression of oxygen radical formation
by its regulatory effects on cell energy metabolism and
stabilization effects on cell membrane phospholipids.
Thus, it is concluded that both endogenous scavenging
systems and regulation of energy metabolism play an
important role in the neuroprotective effects against
oxygen free radicals (14).
Especially in advanced lung and breast cancer patients,
serum acylcarnitine concentrations were decreased and
renal clearance of acylcarnitine was elevated (26). Since it
is generally recognized that serum and urine carnitine
profiles change with the metabolic state, the higher
acylcarnitine clearance and acid insoluble acylcarnitine
(AIAC) excretion in cancer patients may reflect their
metabolic state (27). It is found that the concentration of
acid soluble acylcarnitine (ASAC) was low in cancer
patients, whereas nonesterified carnitine (NEC) and AIAC
levels were similar to those of non-cancer patients (26).
The decreased concentrations may have been due to
increased utilization of lipids, decreased production and
increased excretion of ASAC or a combination of these
(26,27). The changes in serum carnitine levels may not
always be indicative of the tissue carnitine concentrations.
It is found that total carnitine concentrations in rats
bearing pituitary tumor Mt T-F4 were significantly higher
than those in non-tumor animals, whereas the serum NEC
concentration was significantly decreased (28).
Palmitoylcarnitine has been reported to inhibit
proliferation of melanoma cells by its interaction with
protein
kinase
C.
Low
concentrations
of
palmitoylcarnitine induce rapid differentiation of
neuroblastoma NB-2a cells in culture. Further, adding
palmitoylcarnitine inhibits proliferation of neuroblastoma
and melanoma (29); however, the potential effect of
palmitoylcarnitine on brain tumor cells necessitates
clinical trials on this issue.
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In the present study, C2, C18 and C18:1 carnitine levels
were significantly decreased in low-grade astrocytomas
when compared with levels in high-grade astrocytomas.
C16:1 carnitine was increased; however, there were no
apparent differences in the other carnitine levels. Most of
the carnitine levels showed decrease in astrocytomas
compared with the GBM group (except C16:1 level in highgrade astrocytomas). Sandikci et al. (9) showed that acid
soluble carnitine levels of grade II and grade III
astrocytomas were found statistically lower than of
glioblastoma. They also stated that acid insoluble carnitine
levels of astrocytomas were lower than of glioblastoma. In
this respect, these findings support our study.
In our study, we analyzed the relation between MDA
and free carnitine, and C2, C3, C4, C5, C6, C8, C10,
C12, C14:1, C14, C16:1, C16, C18:1, C18, C20:4
carnitine levels in glial tumors. We found that there was

Turk J Med Sci

a significant correlation only between MDA and C20:4
carnitine levels in GBM. As MDA levels increased, C20:4
levels also increased (p = 0.000, r = 0.916). This
supports the claim that the unsaturated fatty acids in the
membrane structure are the most affected in lipid
peroxidation. No significant correlation was found
between the other groups.
As a result, measurement of only carnitine-MDA
relation did not reveal any significant correlation. Detailed
studies including antioxidant structures and other
parameters that are related with tumor cell metabolism
are necessary.
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